Download Quiz - UConn School of Pharmacy

Questions for TSOA’s Webinar
1. Which two of the following TSOA’s requires a 5- to 10-day lead-in with anticoagulation by
infusion or injection when treating a patient with a DVT/PE? (you must select both agents
correctly to receive full credit for this question)
a. Apixaban
b. Rivaroxaban
c. Edoxaban
d. Dabigatran
e. All of the above
2. Which of the following TSOA’s is a prodrug?
a. Dabigatran
b. Rivaroxaban
c. Apixaban
d. Edoxaban
3. Which of the following TSOA’s bioavailability substantially increases when it is taken with food
(largest meal of the day)?
a. Edoxaban
b. Rivaroxaban
c. Dabigatran
d. Apixaban
4. Which TSOA has the highest percentage of the drug renally cleared compared to the other
TSOA’s in this drugs kinetic profile?
a. Rivaroxaban
b. Apixaban
c. Edoxaban
d. Dabigatran
5. What type of patient would be considered a good candidate to consider TSOA therapy?
a. Documented warfarin allergy
b. History of poor INR control on warfarin despite good compliance
c. Considerable barriers to routine monitoring, such as physical or transportation issues
d. Document and confirmed warfarin failure such as an ischemic stroke while consistently
therapeutic on warfarin
e. All of the above
6. Prior to initiating any TSOA the patient should be evaluated for which the following?
a. Renal Clearance
b. Appropriate and approved indication for the specific TSOA agent
c. Review of patient medication profile to check for potentially significant drug-drug
interactions
d. Adequate insurance coverage or prescription assistance before starting the TSOA agent
e. All of the above
7. Of all the recent TSOA agents that we discussed during this presentation which agent was the
first new oral anticoagulant approved in the US in over 50 years?
a. Dabigatran
b. Rivaroxaban
c. Apixaban
d. Edoxaban
8. What TSOA agent is classified as a direct thrombin inhibitor?
a. Rivaroxaban
b. Apixaban
c. Dabigatran
d. Edoxaban
9. Which of the follow TOA’s has a reversal agent approved and available on the market?
a. Edoxaban
b. Warfarin
c. Dabigatran
d. B & C
e. None of the above
10. The reversal agent idarucizumab is administered by the following route?
a. Oral (PO)
b. Subcutaneous
c. Intravenous (IV)
d. sublingual